SCHEMBL9955480

SCHEMBL9955480

O=C(c1cccs1)C(S(=O)(=O)O)S(=O)(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.53
CES1 P23141 2/20 0.53
KEAP1 Q14145 1/20 0.53
DAO P14920 1/20 0.50
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 1/20 0.47
HDAC1 Q13547 1/20 0.47
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGDS O60760 1/20 0.44
GSK3B P49841 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26056789 0.75 CES2 (0.66) CES2CES1KEAP1DAONPC1
SCHEMBL15436893 0.74 RAB9A (0.43) CES2CES1KEAP1DAONPC1
SCHEMBL1937375 0.74 RAB9A (0.58) CES2CES1KEAP1DAONPC1
SCHEMBL8561978 0.74 CES2 (0.58) CES2CES1KEAP1DAONPC1
SCHEMBL3999322 0.74 CES2 (0.58) CES2CES1KEAP1DAONPC1
SCHEMBL619898 0.74 CES2 (0.64) CES2CES1KEAP1DAONPC1
SCHEMBL23793030 0.72 RAB9A (0.56) CES2CES1KEAP1DAONPC1
SCHEMBL29077328 0.72 CES2 (0.61) CES2CES1KEAP1DAONPC1
Sulfuric Acid SCHEMBL28129454 0.72 CES2 (0.56) CES2CES1KEAP1DAONPC1
SCHEMBL14490190 0.72 CES2 (0.61) CES2CES1KEAP1DAONPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2654665-A2 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH (DE) 2013-10-30 EP disclosed
WO-2012083906-A2 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA PHARMA GESELLSCHAFT FÜR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) 2012-06-28 WO disclosed